Home > Publications > Papers of Interest > Metronomic in children
Metronomic in children
Metronomics is as effective as current standard for recurrent high risk neuroblastoma
Frank Berthold, Marc Hömberg, Inna Proleskovskaya, Pavel Mazanek, Margarita Belogurova, Angela Ernst & Jaroslav Sterba from the Department of Pediatric Oncology and Hematology, University of Cologne, Germany; Department of Pediatric Oncology and Hematology, University of Minsk, Belarus; Department of Pediatric Oncology and Hematology, University of[...]
More on propranolol and neuroblastoma
More on propranolol and neuroblastoma
Two recent studies published in the Journal of Pediatric Surgery and in Oncotarget have confirmed our work on the potential role of betablocker (Pasquier and al. Br J Cancer 2013) in the treatment of neuroblastoma.
Indeed, Xu T and al. from the Department of Surgery of Children’s Hospital, Fudan University,[...]
Myelodysplastic syndrome-post-cytotoxic therapy for pediatric low-grade glioma
A case report entitled : Myelodysplastic syndrome-post-cytotoxic therapy for pediatric low-grade glioma authored by Phoebe Power, Susannah Payne, Rebecca Walsh, Adam Nelson & Neevika Manoharan from Department of Pediatric Oncology, Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Boston, USA and Kids Cancer Centre, Sydney[...]
Nontoxic, fiscally responsible, future of oncology: could it be beginning in the Third World?
J Pediatr Hematol Oncol. 2011 Jan;33(1):1-3.
Nontoxic, fiscally responsible, future of oncology: could it be beginning in the Third World?
Klement GL, Kamen BA.
Oral etoposide and cyclophosphamide: A low-cost palliative metronomic chemotherapy in advanced pediatric cancers
An article entiled "Oral etoposide and cyclophosphamide: A low-cost palliative metronomic chemotherapy in advanced pediatric cancers" has just been published in Cancer Research, Statistics, and Treatment by Kiran Kumar, Venkatraman Radhakrishnan, Manikandan Dhanushkodi, Jayachandran, Perumal Kalaiyarasi, Nikita Mehra, Arun Rajan Kumar, Gangothri[...]
Oral Metronomic Maintenance Therapy Can Improve Survival in High-Risk Neuroblastoma Patients Not Treated with ASCT or Anti-GD2 Antibodies
Xiaofei Sun, Zijun Zhen, Zhuowei Liu and collaborators from the State Key Laboratory of Oncology in South China and Sun Yat-sen University Cancer Center, Guanghzou China have just published in Cancers the results from their clinical experience with metronomic maintenance in neuroblastoma entitled :Oral Metronomic Maintenance Therapy Can Improve[...]
Oral Metronomic Topotecan Sensitizes Crizotinib Antitumor Activity in ALKF1174L Drug-Resistant Neuroblastoma Preclinical Models.
Zhang L, Wu B, Baruchel S. from the New Agent and Innovative Therapy Program, and the Department of Paediatric Laboratory Medicine, The Hospital for Sick Children, Toronto, Canadahave published in Translational Oncology an artivle entitled : Oral Metronomic Topotecan Sensitizes Crizotinib Antitumor Activity in ALKF1174L Drug-Resistant Neuroblastoma[...]
Pharmacokinetics of metronomic temozolomide in cerebrospinal fluid of children with malignant central nervous system tumors
In a recent paper entitled Pharmacokinetics of metronomic temozolomide in cerebrospinal fluid of children with malignant central nervous system tumors and published in Cancer Chemotherapy Pharmacology, Sören Büsker, Walter Jäger, Stefan Poschner, Lisa Mayr , Valentin Al Jalali, Johannes Gojo, Amedeo A Azizi, Sami Ullah, Muhammad Bilal, Lobna El Tabei,[...]
Phase 1 study of sirolimus in combination with oral cyclophosphamide and topotecan in children with relapsed/refractory solid tumors.
Vo KT, Karski EE, Nasholm NM, Allen S, Hollinger F, Gustafson WC, Long-Boyle JR, Shiboski S, Matthay KK, and DuBois SG1 from the Department of Pediatrics, UCSF Benioff Children’s Hospital, University of California, San Francisco School of Medicine, San Francisco, CA; the Department of Clinical Pharmacy, UCSF Benioff Children’s Hospital, University of[...]
Phase II metronomic Vinblastine for Chemotherapy-Naïve Children With Progressive Low-Grade Glioma
A recent artivle published inthe JCO by Alvaro Lassaletta and al. report on the use of metronomic weekly vinblastine in 54 children with naive LGG.Five-year overall survival and progression-free survival (PFS) rates were 94% and 53% respectively, for the entire cohort with better outcome for NF1 patients. Treatment was well tolerated and quality of[...]
